Procept Biorobotics CORP

PROCEPT BioRobotics Corporation shareholders elected three directors and ratified the appointment of its independent auditor at the 2026 Annual Meeting.

Procept Biorobotics reported a 20% increase in first-quarter revenue to $83.1 million, driven by strong U.S. system sales and improved pricing, alongside a 30% rise in U.S. procedures.

PROCEPT BioRobotics outlines strong financial growth, margin expansion, and a clear path to profitability by 2027, alongside strategic expansion into the prostate cancer market.

PROCEPT BioRobotics reported strong Q4 2025 procedure volume and system sales, alongside a reset of 2026 revenue guidance due to strategic realignments.

PROCEPT BioRobotics Corporation announced robust third-quarter 2025 financial results, with total revenue increasing 43% year-over-year and issued optimistic 2026 revenue guidance.

PROCEPT BioRobotics Corporation's Compensation Committee approved amendments to executive Change of Control and Severance Agreements, enhancing benefits for non-CEO officers.

PROCEPT BioRobotics reports 20% revenue growth to $83.1 million for Q1 2026, driven by increased system sales and utilization.

PROCEPT BioRobotics reported a 43% revenue increase to $83.3 million in Q3 2025, driven by strong U.S. sales, though net losses continued at $21.4 million.

PROCEPT BioRobotics Corporation reported significant revenue growth and improved gross margins for the second quarter and first half of 2025, driven by increased system sales and utilization of its BPH treatment technology.

PROCEPT BioRobotics Corporation announces a 55% increase in revenue for Q1 2025, driven by growth in system sales and utilization of Aquablation therapy.

PROCEPT BioRobotics Corporation announced a 66% increase in revenue for the third quarter of 2024, driven by strong sales of its Aquablation therapy systems and consumables, and the launch of its next-generation HYDROS Robotic System.

PROCEPT BioRobotics Corporation announced a 70% increase in revenue for the six months ended June 30, 2024, driven by increased sales of their AquaBeam Robotic System and related consumables.

PROCEPT BioRobotics Corporation announced significant revenue growth in its 2025 annual report, driven by increased adoption and utilization of its robotic systems for BPH treatment, despite continued net losses.

PROCEPT BioRobotics Corporation files an amendment to its annual report to include its Insider Trading Compliance Policy and Procedures, which was inadvertently omitted from the original filing.

Procept BioRobotics' 2024 10-K filing reveals significant revenue growth driven by increased adoption of their Aquablation therapy, alongside a reduction in net losses.

Procept Biorobotics reports significant revenue growth for fiscal year 2023, driven by increased adoption of its Aquablation therapy.

Director Antal Rohit Desai reported a transaction involving the acquisition of 3,315 shares of common stock and 5,853 stock options in PROCEPT BioRobotics Corp.

Director Amy Dodrill of PROCEPT BioRobotics Corp. reported the acquisition of restricted stock units and stock options on June 9, 2026.

Mary Garrett, a Director at PROCEPT BioRobotics Corp, acquired restricted stock units and a stock option, as detailed in a recent SEC Form 4 filing.

Director Taylor C. Harris acquired 3,315 shares of common stock and was granted 5,853 stock options in PROCEPT BioRobotics Corp.

PROCEPT BioRobotics Corp reports a Form 4 filing detailing stock and option awards to Director Elisabeth Little.

Director Frederic H. Moll of Procept BioRobotics Corp. reported the acquisition of 3,315 shares of common stock and the grant of 5,853 stock options on June 9, 2026.

PROCEPT BioRobotics Corporation has issued its 2026 proxy statement detailing director elections, executive compensation, and the ratification of its independent auditor.

PROCEPT BioRobotics Corporation has filed a definitive proxy statement with the SEC.

PROCEPT BioRobotics Corporation will hold its 2025 annual meeting of stockholders virtually on June 10, 2025, to elect directors, ratify the selection of its accounting firm, and approve executive compensation.

PROCEPT BioRobotics Corporation will hold its 2024 annual meeting of stockholders virtually on June 4, 2024, to elect directors, ratify the selection of its accounting firm, and approve executive compensation.

PROCEPT BioRobotics Corporation has filed a definitive proxy statement with the SEC.

AllianceBernstein L.P. has filed a Schedule 13G, reporting beneficial ownership of 147,327 shares of PROCEPT BioRobotics Corp. common stock, representing 0.3% of the class.

Vanguard Capital Management has reported beneficial ownership of 5% of PROCEPT BioRobotics Corp. common stock as of March 31, 2026.

The Vanguard Group reported 0% beneficial ownership in PROCEPT BioRobotics Corp following an internal realignment and disaggregated reporting strategy.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 2.9% in PROCEPT BIOROBOTICS CORP, indicating a reduction from previous holdings.

T. Rowe Price Investment Management, Inc. reports a 5.9% beneficial ownership stake in PROCEPT BIOROBOTICS CORP common stock.

BNP Paribas Asset Management Holding S.A. has reported a 5.5% beneficial ownership stake in PROCEPT BioRobotics Corp, totaling 3,094,649 shares of common stock.